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Abstract
Background: Melanoma is an aggressive tumor with increasing incidence. To develop accurate prognostic markers 
and targeted therapies, changes leading to malignant transformation of melanocytes need to be understood. In the 
Xiphophorus melanoma model system, a mutated version of the EGF receptor Xmrk (Xiphophorus melanoma receptor 
kinase) triggers melanomagenesis. Cellular events downstream of Xmrk, such as the activation of Akt, Ras, B-Raf or 
Stat5, were also shown to play a role in human melanomagenesis. This makes the elucidation of Xmrk downstream 
targets a useful method for identifying processes involved in melanoma formation.
Methods: Here, we analyzed Xmrk-induced gene expression using a microarray approach. Several highly expressed 
genes were confirmed by realtime PCR, and pathways responsible for their induction were revealed using small 
molecule inhibitors. The expression of these genes was also monitored in human melanoma cell lines, and the target 
gene FOSL1 was knocked down by siRNA. Proliferation and migration of siRNA-treated melanoma cell lines were then 
investigated.
Results: Genes with the strongest upregulation after receptor activation were FOS-like antigen 1 (Fosl1), early growth 
response 1 (Egr1), osteopontin (Opn), insulin-like growth factor binding protein 3 (Igfbp3), dual-specificity phosphatase 
4 (Dusp4), and tumor-associated antigen L6 (Taal6). Interestingly, most genes were blocked in presence of a SRC kinase 
inhibitor. Importantly, we found that FOSL1, OPN, IGFBP3, DUSP4, and TAAL6 also exhibited increased expression levels in 
human melanoma cell lines compared to human melanocytes. Knockdown of FOSL1 in human melanoma cell lines 
reduced their proliferation and migration.
Conclusion: Altogether, the data show that the receptor tyrosine kinase Xmrk is a useful tool in the identification of 
target genes that are commonly expressed in Xmrk-transgenic melanocytes and melanoma cell lines. The identified 
molecules constitute new possible molecular players in melanoma development. Specifically, a role of FOSL1 in 
melanomagenic processes is demonstrated. These data are the basis for future detailed analyses of the investigated 
target genes.
Background
Melanoma development is a complex process based on
many epigenetic and genetic factors. The most frequent
genetic changes in human melanoma are activating muta-
tions in either BRAF or NRAS. This is often combined
with inactivating mutations in phosphatase and tensin
homologue (PTEN) or cyclin-dependent kinase inhibitor
2 a (CDKN2A) [1].
The search for other characteristics shared between
human melanoma from different individuals has revealed
the importance of several proteins influencing melanoma
cell cycle progression, apoptosis, cell adhesion, and
angiogenesis. Examples are cyclin-dependent kinase 4
(CDK4), AKT, β-catenin, melanoma inhibitory activity
protein (MIA), and Ephrin-A1 (EFNA1) [1,2]. Still, the
search for further melanoma-relevant genes is a promis-
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ing concept with potential therapeutic value, and several
recent studies applying high-throughput gene expression
profiling have associated previously unknown candidate
genes with melanoma progression [3-5]. However, the
comparability among different studies is low due to the
variability of human tumor biopsies and the cultivation-
dependent changes in melanoma-derived cell lines.
By contrast, animal models represent genetic systems
with well defined genetic background where tumorigene-
sis is initiated by known molecular events. In the
Xiphophorus  fish melanoma model, a single oncogenic
epidermal growth factor receptor, termed Xiphophorus
melanoma receptor kinase (xmrk) is responsible for spon-
taneously developing melanoma [6].
Xmrk uses several signaling cascades that are also
involved in human melanomagenesis, e.g. the phospho-
inositide-3 kinase (PI3K) pathway and the RAS-RAF-
MAPK cascade. Other molecules, e.g. the signal trans-
ducer and activator of transcription 5 (STAT5) and osteo-
pontin (OPN), were first identified as essential mediators
of Xmrk signaling and were subsequently shown to be
relevant in human melanomagenesis as well [7-10]. These
findings prompted us to search for novel Xmrk-regulated
genes that may potentially play a role in human mela-
noma development.
It was shown many times that Xmrk signaling is highly
comparable between its natural host cells - pigment cells
from Xiphophorus - and mammalian cells that ectopically
express the receptor [11-14]. Xmrk is permanently active
due to its dimerization. However, to be able to differenti-
ate between inactive and active receptor signaling, we are
using the melanocytes cell line melan-a stably expressing
a chimeric protein consisting of the extracellular part of
EGFR ("HER") and the cytoplasmic part of Xmrk ("mrk")
(melan-a "HERmrk" or shortly "Hm"). Melan-a cells lack
endogenous EGFR, and the stimulation of Hm cells with
EGF results in specific induction of Xmrk-dependent sig-
naling pathways and tumorigenic transformation.
Here, we have analyzed gene expression profiles of
stimulated versus unstimulated cells using a microarray
approach. The genes with the strongest regulation in
response to activated HERmrk were FOS-like antigen 1
(Fosl1), early growth response 1 (Egr1), osteopontin
(Opn), insulin-like growth factor binding protein 3
(Igfbp3), dual-specificity phosphatase 4 (Dusp4), and
tumor-associated antigen L6 (Taal6). We investigated the
pathways regulating these genes and analyzed their
expression in human melanoma cell lines. We further-
more found that the knockdown of FOSL1 reduced pro-
liferation and migration of human melanoma cell lines.
Thus, this study reveals FOSL1 as new potential molecu-
lar player in melanomagenesis by using the Xmrk mela-
noma model.
Methods
RNA isolation for microarray analysis
Cells were starved for 72 h with DMEM containing 2.5%
dialyzed FCS. After stimulation with 100 ng/ml human
EGF (hEGF) (tebu-bio, Le Perray en Yvelines, France) for
indicated times, RNA was extracted from the cells using
the RNeasy kit (Qiagen, Valencia, CA) according to the
manufacturer's instructions. Only RNA samples with an
A260/A280 ratio > 1.8 were used for microarray hybridiza-
tion.
Microarray probe preparation and hybridization
Transcriptional profiling was done on a microarray con-
taining 21,168 DNA spots from the mouse cDNA library
NIA 15 k and 7.4 k Mouse cDNA Clone Set (National
Institute on Aging, Bethesda, MD). Total RNA was puri-
fied with RNeasy spin columns (Qiagen). After mRNA
amplification with MessageAmp II aRNA Kit (Ambion,
Austin, TX USA), Cy3- and Cy5-labeled cDNA probes
were generated using the CyScribe cDNA Post-Labelling
Kit (GE Healthcare, Amersham Place, Little Chalfont
England). The labeled probes were purified with
QIAquick PCR Purification Kit (Qiagen, Hilden, Ger-
many), combined in hybridization buffer (0.2% SDS, 4.5×
SSC) and hybridized on the microarray for 16 h at 55°C.
Finally , the chips were washed at a stringency of 0.1 ×
SSC/0.1% SDS, dried by centrifugation, scanned and
quantified using Scan Array Express (Perkin Elmer,
Waltham, MA USA).
Data analysis
Each experiment was performed as sandwich hybridiza-
tion, i.e. instead of a coverslip, a second microarray slide
was used. This provides a replicated measurement for
each hybridization that can be used for quality control
and that reduces technical variability. For each spot,
median signal and background intensities for both chan-
nels were obtained. To account for spot differences, the
background-corrected ratio of the two channels was cal-
culated and log2 transformed. To balance the fluores-
cence intensities for Cy3 and Cy5 as well as to allow for
comparison of expression levels across experiments, the
raw data were standardized. We used the print-tip-LOW-
ESS normalization to correct for inherent bias on each
chip. Expression data and gene annotations were stored
in Array Express http://www.ebi.ac.uk/arrayexpress/
(accession: E-MEXP-1311), which complies with MIAME
(minimal information about a microarray experiment)
guidelines. The R environment software http://www.r-
project.org/ was used for data analysis. To find differently
expressed genes, changes in mRNA expression levels in
stimulated versus unstimulated cells were calculated for
each gene. The normalized data were filtered due to strictTeutschbein et al. BMC Cancer 2010, 10:386
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quality criteria and analyzed using Microsoft Excel. For
experimental comparisons, genes showing at least a two-
fold change were chosen.
Cell culture
Mouse melanocytes transfected with HERmrk [melan-a
Hm cells, [13]] or with human EGF receptor (melan-a
HER) were cultured as described previously [14]. The
human immortalized melanocyte cell line Hermes 3a
(kindly provided by D. Bennett) was grown in RPMI sup-
plemented with penicillin (400 U/ml), streptomycin (50
μg/ml), L-glutamine (300 μg/ml), TPA (200 nM), cholera
toxin (2 pM), hSCF (10 ng/ml), endothelin (10 nM), and
10% FCS, as previously described [15]. Human melanoma
cell lines Mel Im, Mel Wei, Mel Juso, and SK-Mel-3 (kind
gifts by A. Bosserhoff) as well as A375, A375M, DX-3,
LT5.1, and SK-Mel-28 were maintained in DMEM sup-
plemented with penicillin (400 U/ml), streptomycin (50
μg/ml), L-glutamine (300 μg/ml) and 10% FCS. Normal
human epidermal melanocytes (NHEM) derived from
foreskin were obtained from PromoCell (Heidelberg,
Germany) and grown in melanocyte growth medium
MGM (PromoCell) under a humidified atmosphere of 5%
CO2 at 37°C. NHEM cells were used between passages 3
and 6.
Expression analysis by realtime PCR and pathway analysis
Cells were starved as described and subsequently stimu-
lated with 100 ng/ml hEGF for indicated times. RNA
extraction from stimulated melan-a Hm cells and human
cell lines was done using Total RNA Isolation Reagent
(ABgene, Epsom, UK) as recommended by the manufac-
turer. For the identification of pathways regulating
expression of candidate genes, the small molecule inhibi-
tors AG1478 (20 μM), PP2 (20 μM), LY294002 (10 μM),
or U0126 (10 μM), respectively, were applied one hour
prior to hEGF stimulation. Cells without inhibitor treat-
ment received the equivalent amount of DMSO. Primary
data of these experiments are available on request. cDNA
was prepared from total RNA using the RevertAid kit
with random hexamer primers (Fermentas, Burlington,
Canada). PCR primers were designed using Primer3 soft-
ware version 0.4.0 http://frodo.wi.mit.edu/primer3/. PCR
was carried out using the iCycler IQ (Bio-Rad, Hercules,
CA). Values for each gene were normalized to expression
levels of β-actin (mouse cell lines) or ribosomal protein
S14 (human cell lines). Primer sequences are available on
request.
Cell lysis and Western blotting
Cells were lyzed and blotted as described [16]. Before
probing with the reference antibody, the blots were
stripped as described. Monoclonal anti-phosphotyrosine
(PY20) was from BD Biosciences (San José, CA). Phos-
pho-p44/42 MAPK (Thr202/Tyr204) antibody was pur-
chased from Cell Signaling Technology (Danvers, MA).
Polyclonal antibodies against FOSL1 (N-17, C-12), EGR1
(C-19), OPN (P-18 and K-20), IGFBP3 (H-98), MKP2 (H-
67), and ERK2 (C-14) were from Santa Cruz Biotechnol-
ogy (Santa Cruz, CA). The MYC-tag antibody (9B11) was
from Cell Signaling Technology (Danvers, MA). Second-
ary antibodies were conjugated with horseradish peroxi-
dase and were directed against mouse (Pierce, Rockford,
IL), rabbit (Bio-Rad) or goat (Abcam, Cambridge, UK).
TAAL6 mouse IgM antibody (10H6) was a kind gift from
S. Roffler. Secondary antibody against mouse IgM was
purchased from Rockland (Gilbertsville, PA).
siRNA transfection
One day before siRNA transfection, melanoma cells were
seeded at a density of 3 × 104 cells per well of a 12-well
plate. For human melanoma cells, commercially available
siRNA against human FOSL1 as well as control siRNA
( S m a r t  P o o l  O n  T a r g e t  P l u s ,  T h e r m o  S c i e n t i f i c )  w e r e
used. siRNA was transfected using X-treme gene trans-
fection reagent (Roche), according to the manufacturer's
recommendations. Downregulation was monitored after
48 h by realtime PCR and Western blot analysis.
BrdU incorporation analysis
Melanoma cell lines A375 and Mel Juso were plated in
triplicate (2.5 × 103 cells per well of a 96-well plate) in
DMEM containing 10% FCS. 48 h after siRNA treatment,
cells were incubated with 10 μM BrdU for 6 h. BrdU
incorporation was then quantified using a colorimetric
BrdU cell proliferation ELISA, as recommended by the
manufacturer (Roche).
Transwell migration assay
2 × 104 A375 or Mel Juso cells were transfected with con-
trol- or FOSL1-specific siRNA. One day later, they were
serum-starved in DMEM containing 1% dialyzed FCS for
24 h and applied to the upper chamber of a transwell
inlay (polycarbonate, 10 mm diameter, 8 μm pores,
Nunc). Migration was measured as described before [14].
The migration rate of the siFOSL1-treated cells was
determined relative to the migration of control cells.
Results
Temporal gene expression profile after Xmrk activation
To obtain a detailed picture of the time course of Xmrk-
dependent gene expression, we compared unstimulated
melan-a HERmrk cells to those stimulated for 15 min-
utes, 1 h, 2 h, 4 h, 8 h or 24 h with EGF.
Successful receptor activation was controlled by West-
ern blot (Additional file 1, Figure S1a) and realtime PCRTeutschbein et al. BMC Cancer 2010, 10:386
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(Additional file 1, Figure S1b). Both assays revealed suc-
cessful stimulation, visible by receptor- and MAPK phos-
phorylation as well as induction of the Xmrk target gene
Opn.
Subsequent microarray analysis revealed the regulation
of 1,273 genes at one or more time-points after HERmrk
stimulation. A gene was considered to be regulated when
changed twofold and more. The complete list of expres-
sion data and gene annotations is available at http://
www.ebi.ac.uk/arrayexpress/ (accession: E-MEXP-1311).
Regulated genes were categorized with respect to their
molecular functions and biological processes according
to the Gene Ontology (GO) terminology. Using the
expression analysis systematic explorer (EASE) software
[ 1 7 ] ,  o v e rr e p r e s e n t a t i o n  o f  g e n e  o n t o l ogy  t e r m s  i n  t h e
1,273 regulated genes compared to the total number of
genes assayed (21,168 spots on the chip) was calculated.
Significantly enriched categories (EASE score < 0.05) are
listed in Additional file 2, Table S1. Among the biological
processes, protein metabolism and protein modification
were particularly enriched, indicating a high metabolic
activity as expected from growth factor stimulated cells,
and enhancement of signal transduction processes. The
most overrepresented molecular function was nucleic
acid binding, encompassing transcription factors and fac-
tors regulating nucleic acid stability.
For further analysis, we chose eleven genes which were
assigned by UniGene and which displayed more than
fourfold regulation at one or more time points. Cyr61,
Igfbp3, and Opn encode secreted proteins. SOS1 is a gua-
nine nucleotide exchange factor. EGR1 and FOSL1 are
transcription factors. EMP1 and TAAL6 are integral
membrane proteins, whereas UBE2I and DUSP4 are
cytosolic enzymes with ubiquitin-conjugating and phos-
phatase activity, respectively. Finally, the transcript with
UniGene ID Mm.204306 has no assigned function. The
time-dependent course of gene expression is depicted in a
color map (Figure 1). Genes regulated at early time points
were for example Cyr61 and Egr1, while Emp1 and Taal6
were regulated at late stimulation times.
To validate the microarray results for highly regulated
genes, we used quantitative realtime PCR (Figure 2). The
time course already observed in the microarray experi-
ment was largely confirmed by realtime PCR analysis.
Sos1,  Ube2i,  Cyr61  and  Egr1  were mainly upregulated
after short stimulation times and decreased later. The
expression of Dusp4 was highest after 1 h, but an upregu-
lation in comparison to the unstimulated control was vis-
ible until 24 h. In case of Igfbp3, the situation looked
slightly different compared to the microarray experiment.
While in the latter the gene was found to be upregulated
after 15 min and again from 4 to 24 h, the transcription
induction was only visible at early times when analyzed
by realtime PCR. For Fosl1, the expression was highest
after 2 h (200-fold) and decreased later, similar to the sit-
uation observed in the microarray experiment. Expres-
sion levels of Emp1 were strongly increasing from 2 to 8 h
and decreased to 4-fold at 24 h. The late-responding
genes Opn, Taal6, and the unnamed gene product (Uni-
Gene ID Mm.204306, data not shown) steadily increased
with the highest levels at 24 h. However, as the gene with
UniGene ID Mm.204306 was retired from UniGene dur-
ing the course of our experiments, we omitted it from
further analyses.
Altogether, in all cases except Igfbp3, transcript induc-
tion as well as its time course was confirmed by realtime
PCR.
Identification of signaling pathways
Previous analyses have revealed that Xmrk transfers sig-
nals via STAT5, the PI3K pathway, the RAS-RAF-MAPK
cascade, and the cytoplasmic SRC kinase family member
FYN [6]. To identify the pathways responsible for modu-
lation of the chosen ten genes, we blocked known Xmrk-
induced pathways using the small molecule inhibitors
AG1478, U0126, PP2, or LY294002. Target gene expres-
sion in presence or absence of the inhibitors was analyzed
by realtime PCR (Additional file 3, Table S2 and, for a
schematic overview, Addditional file 4, Figure S2).
As expected, the inducing effects of EGF on all genes
were abrogated when HERmrk was inhibited by AG1478.
While regulation of Emp1,  Fosl1, and Opn  was both
MEK- and SRC family kinase-dependent, induction of
Sos1,  Ube2I,  Dusp4, and Taal6  was only restrained by
inhibiting SRC-family kinases with PP2. Egr1 expression
could only be decreased after MEK inhibition, and Cyr61
transcription was dependent on MEK and PI3K. Finally,
expression of Igfbp3 was decreased after application of
each of the inhibitors.
Expression of candidate genes in human melanoma cell 
lines
For further analysis, we focused on six significantly regu-
lated genes from four different functional groups: the
transcription factors FOSL1 and EGR1, the secreted pro-
teins OPN and IGFBP3, the phosphatase DUSP4, and the
membrane protein TAAL6. We monitored their expres-
sion levels in human melanoma cell lines compared to
normal human epidermal melanocytes (NHEM). For this
analysis we chose eight different cell lines, containing
either activating N-RAS- (DX-3, LT5.1 and Mel Juso) or
B-RAF mutations (A375, A375M, Mel Wei, Mel Im, SK-
Mel-3 and SK-Mel-28).
Realtime PCR revealed a significantly higher expression
of FOSL1, OPN, IGFBP3, DUSP4 and TAAL6 in most of
the melanoma cell lines compared to normal melanocytes
(Figure 3a). The sole exception was observed in case ofTeutschbein et al. BMC Cancer 2010, 10:386
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EGR1, where only A375M cells displayed a significant
upregulation. At the level of protein, NHEM displayed
almost no expression of most of the proteins, whereas in
the majority of examined melanoma cell lines FOSL1,
IGFBP3 and DUSP4 were strongly expressed (Figure 3b).
EGR1, OPN and TAAL6 were expressed in at least two
third of the cell lines, but not in NHEM cells.
As Xmrk is an orthologue of the human EGF receptor,
we wanted to elucidate if the upregulation of the identi-
fied target genes is a shared property between human
EGFR and Xmrk/HERmrk. Of the 10 C-terminal SH2
docking sites of human EGFR, most of them with over-
lapping substrate specifity, 7 are conserved in Xmrk, sug-
gesting at least partial functional similarity. The
melanoma cell line A375 reportedly expresses human
EGFR and responds to addition of EGF [18]. When
induction of FOSL1, EGR1, OPN, IGFBP3, DUSP4 and
TAAL6 was monitored after EGF stimulation between 15
minutes and 24 h, only the fast responding FOSL1 and
EGR1 genes were found to be induced (Figure 4a and data
not shown). Compared to HERmrk-expressing melano-
cytes,  FOSL1  upregulation was weaker in A375, while
EGR1 induction was even stronger (compare Figure 4a
and Figure 2). As A375 cells express oncogenic BRAFV600E
and already underwent the process of transformation, it
is possible that ongoing endogenous aberrant signaling
concealed EGFR stimulation in this cell line. For this rea-
son, and to gain a better comparison to the untrans-
formed melan-a HERmrk cells, we used melan-a cells
stably transfected with human EGFR ("melan-a HER")
and performed an experiment similar to the one per-
formed with A375 cells (Figure 4b). Here, all investigated
genes except Igfbp3 were upregulated in response to EGF.
Apart from the downregulated Opn and Taal6 values at
24 h, the extent and time course of stimulation were com-
parable between HERmrk and HER stimulation (Figures
2 and 4b).
Among the genes identified, the protein encoded by
FOSL1 constitutes an interesting candidate with a poten-
tial effect on melanoma biology. It is part of the AP-1
complex, which is a functional downstream target of the
MAP kinase pathway that is commonly activated in mela-
noma [19]. Furthermore, c-JUN, which might be a poten-
tial binding partner for FOSL1 in the AP-1 complex, is
highly expressed in most melanoma and is required for
tumor transformation [20-22]. The human protein atlas
database constitutes a platform which offers an extensive
amount of protein expression data gained from a large
Figure 1 Color map of Xmrk-specific gene expression. Eleven highly regulated genes are itemized. RNA was extracted at time 0 (no hEGF) and at 
indicated time points after hEGF addition. The color code shows differences in the expression of the eleven genes regulated > 4-fold in the range of 
+3 (red) to -3 (green).
Sos1, son of sevenless homolog 1; Ube2i, ubiquitin-conjugating enzyme E2I; Cyr61, cysteine rich angiogenic inducer 61; Egr1, early growth response 1; 
Dusp4, dual specificity phosphatase 4; Igfbp3, insulin-like growth factor binding protein 3; Fosl1, FOS-like antigen 1; Emp1, epithelial membrane protein 
1; Opn, osteopontin; Taal6, tumor-associated antigen L6. NA: not annotated.Teutschbein et al. BMC Cancer 2010, 10:386
http://www.biomedcentral.com/1471-2407/10/386
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Figure 2 Validation of microarray results of ten candidate genes by quantitative realtime PCR. RNA was extracted at indicated time points after 
HERmrk stimulation with hEGF. Expression of candidate genes was compared to unstimulated cells. The fold change of transcript, referred to the un-
stimulated control, which is set as 1, is indicated on the y axis. Mouse β-actin served as reference gene. Significant regulation (p < 0.05) is marked by 
an asterisk; two asterisks indicate highly significant regulation (p < 0.001) (Student's t-test, paired, one-tailed).Teutschbein et al. BMC Cancer 2010, 10:386
http://www.biomedcentral.com/1471-2407/10/386
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Figure 3 Expression of candidate genes in human melanoma cell lines. a, Realtime PCR was performed to determine FOSL1, EGR1, OPN, IGFBP3, 
DUSP4 and TAAL6 expression in human melanoma cell lines compared to NHEM cells. Fold change of transcript, referred to NHEM cells, is indicated. 
β-actin was used as reference gene. Significant (p < 0.05) or highly significant (p < 0.001) regulation are marked by one or two asterisks, respectively 
(Student's t-test, paired, one-tailed).
b, Western blot analysis of the candidate genes in human melanoma cell lines. Expression of ERK2 served as loading control. Please note that the order 
of cell lines differs from A. On the OPN blot, the lower band represents the OPN protein. For TAAL6, the upper band corresponds to the protein of the 
expected size.Teutschbein et al. BMC Cancer 2010, 10:386
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variety of normal human tissues, cancer tissues and cell
lines [23,24]. Here, FOSL1 expression is low or non-
detectable in most tissues, and moderate in epidermal
skin cells. Among melanoma tissues, two thirds express
moderate or high levels of the protein, and both mela-
noma cell lines investigated also show high expression
http://www.proteinatlas.org/
tissue_profile.php?antibody_id=4396&g_no=ENSG0000
0175592. These data confirm our own observations,
namely the increase of FOSL1 expression in transformed
or activated pigment cells. In our study, FOSL1 protein
levels were not only upregulated in mouse melanocytes
e x p r e s s i n g  H E R m r k,  b u t  w e r e  a l s o  e l e v a t e d  i n  h u m a n
melanoma cell lines compared to the human melanocyte
Figure 4 Expression of candidate genes in response to stimulation of human EGFR. Realtime PCR was performed to determine expression levels 
of FOSL1 and EGR1 in the human melanoma cell line A375 (a) or expression levels of Fosl1, Egr1, Opn, Dusp4, and Taal6 in HER-transgenic melan-a cells 
(b), stimulated with EGF for the indicated times. The fold change of transcript, referred to the unstimulated controls, is indicated on the y axis. Murine 
and human β-actin were used as reference genes. Significant (p < 0.05) or highly significant (p < 0.001) regulation are marked by one or two asterisks, 
respectively (Student's t-test, paired, two-tailed).Teutschbein et al. BMC Cancer 2010, 10:386
http://www.biomedcentral.com/1471-2407/10/386
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Figure 5 MAPK-pathway dependent expression of FOSL1 and effects of FOSL1 knockdown on proliferation and migration of melanoma 
cells A375 and Mel Juso. a, Western blot analysis of FOSL1 levels in murine melanocytes (left) and human melanocytes and melanoma cell lines 
(right). Murine melan-a and melan-a HERmrk cells were starved for 2 days before EGF and U0126 were added for 24 hours. Human melanoma cells 
were treated with U0126 for 24 hours. P-ERK1/2 levels were used to verify MEK inhibition, ERK2 was used as reference.
b, Realtime PCR analysis (left) and Western blot analysis (right) of FOSL1 expression levels after treatment of the indicated cell lines with control siRNA 
or FOSL1-specific siRNA. For realtime PCR analysis, control siRNA-treated FOSL1 levels were set as 1. For the Western blot, β-actin was used as reference.
c, BrdU incorporation of A375 and Mel Juso melanoma cells transfected with control siRNA or FOSL1-specific siRNA.
d, Migration of A375 and Mel Juso cells treated with FOSL1-specific siRNA relative to control siRNA-treated cells.
Significant (p < 0.05) or highly significant (p < 0.001) differences between control and FOSL1 siRNA treated cells are marked by one or two asterisks, 
respectively (Student's t-test, paired, two-tailed).Teutschbein et al. BMC Cancer 2010, 10:386
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cell line Hermes3a (Figure 5a) and NHEM cells (Figure
3b). Inhibition of MEK strongly reduced FOSL1 protein
in HERmrk-transgenic cells as well as in the human cell
lines A375 and Mel Juso (Figure 5a). This suggests that
MAPK pathway activation by BRAFV600E (as in A375) and
by NRASQ61K (as in Mel Juso) is important in maintaining
FOSL1 expression. To investigate the effect of FOSL1 on
melanoma growth, we downregulated FOSL1 in the mel-
anoma cell lines A375 and Mel Juso using siRNA (Figure
5b). Proliferation was monitored by BrdU incorporation
assay, which indicates the number of cells in S phase (Fig-
ure 5c). In both cell lines, BrdU incorporation was signifi-
cantly reduced in presence of FOSL1 siRNA (79 and 77%,
respectively). Furthermore, the migration capacity of Mel
Juso cells was reduced to 66% (Figure 5d).
Discussion
Here we describe the regulation of potential novel mela-
noma candidate genes using an inducible version of the
EGFR orthologue Xmrk.
Ten of the most strongly regulated genes were exam-
ined in presence of pathway inhibitors to determine the
respective signal transduction chain responsible for their
regulation. Eight out of ten genes were at least partly con-
trolled by members of the SRC kinase family, while six
genes were induced by the MAPK pathway and only two
genes by the PI3 kinase pathway. Usually, gene regulation
was reduced by inhibition of more than one pathway,
which indicates an interplay between the simultaneously
activated pathways. Although we could only perform the
inhibitor analysis with a small group of genes, which is
not representative of the overall mode of gene regulation,
it was surprising that such a high gene number was regu-
lated by SRC kinases. From previous studies it is known
that FYN is the only SRC family kinase member that is
directly activated by Xmrk [25]. FYN prevents inactiva-
tion of MAPK by reducing MAPK phosphatase 1 (MKP-
1) expression, but also stabilizes the complex between
Xmrk and the p85 subunit of PI3K [13,26]. This might
explain why in our study many genes are not only affected
by SRC family kinase inhibition, but also by blocking
MEK or PI3K. Although the effect of SRC kinases on gene
expression has not yet been investigated in human mela-
noma, accumulating data indicate that this pathway plays
a vital role for the malignant cells. Specifically, it was
shown by kinase activity profiling that SRC is activated in
primary human melanoma and its inhibition leads to
reduced growth [27]. Activated SRC was also detected in
cutaneous, mucosal and metastatic melanoma, and its
inhibition by dasatinib or bosutinib blocked the growth
of several melanoma cell lines [28,29]. Furthermore, an
active SRC family kinase-focal adhesion kinase complex,
responsible for migration and metastatic spread, was
described both for the Xmrk model and for human mela-
noma [14,30]. Together with our own data, this depicts an
important melanomagenic role for SRC kinases in general
and raises the necessity to further scrutinize SRC family
kinase-dependent gene regulation in human melanoma.
Among the identified genes, expression of Egr1, Dusp4,
Igfbp3, Fosl1, Opn, and Taal6  were investigated more
closely. Importantly, five of these genes have been found
to be upregulated in several different melanoma microar-
ray studies. Recently, B-RAFV600E-dependent genes were
analysed by MEK inhibition or BRAF siRNA in human
melanoma cell lines, revealing regulation of the transcrip-
tion factors FOSL1 and EGR1 by this pathway [31]. Inter-
estingly, EGR1 belongs to a distinct group of salivary
marker genes expressed in melanoma-bearing mice [32].
IGFBP3 was more strongly expressed in metastatic and
cutaneous melanoma compared to melanocytes [33]. Its
function seems to depend on the cellular context, as both
anti- and pro-tumorigenic roles were attributed to this
protein [34,35].
DUSP4 and OPN were upregulated in cutaneous mela-
noma in comparison to normal skin or benign nevi [5].
DUSP4 is a dual phosphatase capable of dephosphorylat-
ing p38, JNK1 and ERK1/2, though JNK1 seems to be the
preferred target in vitro [36]. Its upregulation may simply
reflect counterregulation of the ERK1/2 pathway in mela-
noma, but has not yet been investigated more closely.
OPN, on the other hand, is a well-known melanoma
marker [37,38] and served as internal control in our stud-
ies.
Finally, in a murine melanoma model with xenografted
A375 cells, EGR1 and OPN expression was enhanced in
cells derived from metastatic melanoma compared to the
parental cell line as well as in metastatic melanoma versus
primary melanoma [39]. The original data of all above-
mentioned microarray studies are available at http://
www.oncomine.org.
Due to the important role of the AP-1 complex in
human melanoma, the lack of information on FOSL1
function in this tumor type, and the MAPK pathway
dependent induction of FOSL1 in melanoma cell lines, we
investigated the effect of FOSL1 knockdown on the pro-
liferation of two melanoma cell lines and found a signifi-
cant inhibition of cells entering the S phase, which was
not due to the induction of apoptosis (data not shown).
Also, migration of Mel Juso cells was decreased after
FOSL1 knockdown. Its function in melanoma was not
described previously, but pro-tumorigenic roles of FOSL1
were reported for other solid cancers [40,41]. Oncogenic
EGFRvIII in glioblastoma cells induces FOSL1 [41], and it
modulates the malignant features of glioma cells, so it
was suggested as target for therapeutic interventions
against malignant gliomas [42]. An oral DNA vaccine
directed against FOSL1 has been demonstrated to effec-Teutschbein et al. BMC Cancer 2010, 10:386
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tively suppress tumor growth, angiogenesis and metasta-
sis in mice injected with breast carcinoma cells [43].
In summary, we used the high overlap between path-
ways downstream of Xmrk and established human mela-
noma pathways for the search of new melanoma-relevant
target genes. Our gene and protein expression results
indicate that Xmrk serves as a suitable model oncogene
for this purpose. As a proof of principle, we investigated
the AP-1 complex component FOSL1 in more detail. We
found that the gene is similarly regulated in a MAPK-
dependent manner by Xmrk and by human melanoma
oncogenes. Importantly, we also could demonstrate a
pro-tumorigenic role of FOSL1 in human melanoma cell
lines, thus confirming the Xmrk oncogene as instrumen-
tal in the search of new melanoma players.
Conclusions
Here we show the receptor tyrosine kinase Xmrk is a
valuable tool to identify target genes and proteins that are
commonly shared between Xmrk-transgenic melano-
cytes and human melanoma cell lines. Interestingly, of
the ten most strongly upregulated genes, the majority was
regulated by SRC kinases, followed by the MAPK path-
way. The transcription factor component gene FOSL1
also belongs to this group of genes. By knocking down
FOSL1, we could demonstrate a pro-proliferative and
pro-migratory function of this protein in melanoma cell
lines. The presented data reveal new potential mela-
noma-relevant genes that can now be investigated for
their melanomagenic function in detail.
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sion of the known Xmrk target Opn was induced after activation of HERmrk 
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ment of differentially expressed genes, are listed. The number of regulated 
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PP2, or LY294002 were applied to inhibit HERmrk, the MAPK kinase MEK, 
SRC-family kinases, or PI3K, respectively. Effects of inhibitors on expression 
of the candidate genes at indicated time points were monitored by real-
time PCR. "+" indicates inhibition of Xmrk-dependent gene expression 
changes, "-" symbolizes that there was no effect.
Additional file 4 Figure S2 Schematic overview of the pathways 
induced by HERmrk and the subsequent induction of indicated 
genes, as shown in this manuscript.. Genes marked with an asterisk were 
only induced by one of the investigated pathways, while the induction of 
genes without asterisk was effected by three (Igfbp3) or two pathways (all 
other genes). The inhibitors used in this manuscript are depicted in red. 
AG1478 inhibits EGFR and its orthologues, including Xmrk. U0126 blocks 
MEK, LY294002 inhibits PI3 kinase, and PP2 inhibits SRC family kinases (FYN 
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